卡培他滨联合替吉奥治疗胰腺癌根治术后患者的效果

目的:观察卡培他滨联合替吉奥治疗胰腺癌根治术后患者的效果。方法:回顾性分析2014年1月至2016年10月60例胰腺癌患者的临床资料。按治疗方案不同分为对照组(n=30,胰腺癌根治术后采用卡培他滨治疗)和观察组(n=30,胰腺癌根治术后采用卡培他滨联合替吉奥治疗),比较两组近期效果、3年累积生存率、不良反应发生率和生命质量评分。结果:治疗后,观察组近期缓解率为46.67%,高于对照组的20.00%;生命质量评分高于对照组;3年累积生存率为56.67%,高于对照组的26.67%,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:卡培他滨联合替吉奥治疗胰腺癌根治术后患者可提高近期缓解率、生命质量评分和3年累积生存率,优于单纯卡培他滨治疗效果。

Effects of Capecitabine combined with Tegafur Gimeracil Oteracil potassium capsulesin treatment of patients after radical resection of pancreatic cancer

Objective:To investigate effects of Capecitabine combined with Tegafur Gimeracil Oteracil potassium capsules in treatment of patients after radical resection of pancreatic cancer.Methods:A retrospective analysis of the clinical data of 60 patients with pancreatic cancer admitted to the hospital from January 2014 to October 2016 was performed.According to different treatment options,they were divided into control group(n=30,treated with Capecitabine after radical resection of pancreatic cancer)and observation group(n=30,treated with Capecitabine combined with Tegafur Gimeracil Oteracil potassium capsules after radical resection of pancreatic cancer)treatment).The short-term effects,3-year cumulative survival rate,incidence of adverse reactions and quality of life score were compared between the two groups.Results:After the treatment,the short-term remission rate of the observation group was 46.67%,which was higher than 20.00%of the control group;the quality of life score was higher than that of the control group;the 3-year cumulative survival rate was 56.67%,which was higher than 26.67%of the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Capecitabine combined with Tegafur Gimeracil Oteracil potassium capsules for the patients with pancreatic cancer after radical resection can improve the short-term remission rate,quality of life score and 3-year cumulative survival rate.Moreover,it is superior to Capecitabine alone.